SOMALOGIC OPERATING CO., INC

SOMALOGIC OPERATING CO., INC specializes in high-throughput proteomic analysis using its proprietary SOMAScan assay technology, delivering precise, multiplexed measurement of thousands of proteins from human plasma and other biofluids. The company provides end-to-end capabilities in biological assay development, reagent manufacturing, and laboratory testing services, with deep expertise in discovery proteomics, biomarker identification, and clinical research support. Its core technical differentiator lies in the SOMAScan platform’s ability to quantify over 7,000 to 11,000 proteins simultaneously with high sensitivity and reproducibility, enabling advanced immunology, oncology, and systems biology research. The firm also designs and manufactures specialized assay kits and analytical instrumentation tailored for biomedical research environments. The company maintains a dominant relationship with the Department of Health and Human Services, consistently supporting HHS agencies such as the Center for Human Immunology with proteomic testing, assay kit procurement, and research consulting services. Work includes large-scale plasma proteome profiling, biomarker validation studies, and laboratory support for immunology and translational medicine programs. The Department of Defense is a minor but active customer, indicating potential interest in defense-relevant biomarker applications. SOMALOGIC operates primarily within biological product manufacturing, biotechnology R&D, and testing laboratory services, positioning itself at the intersection of life sciences research and clinical diagnostics. It serves the biomedical research, pharmaceutical development, and public health sectors with proprietary proteomic tools that bridge discovery and translational science. As a privately held entity based in Boulder, Colorado, SOMALOGIC operates without federal certifications but maintains a focused presence in the federal research and development market through its specialized, IP-protected technologies and consistent delivery of high-complexity proteomic services to federal science agencies.